Transplantation with human placental stem cells improves diabetes complications in rats

August 30, 2016

Putnam Valley, NY. (August 30, 2016) - In an effort to determine if stem cell therapy can prevent or improve a condition called "diabetic foot" caused by poor blood flow in patients with diabetes, a team of researchers in China has found that transplanting human placenta-derived mesenchymal stem cells (MSCs) into rats modeled with diabetes can affect blood vessel growth, potentially improving blood flow and preventing critical limb ischemia (CLI), a condition that results in diabetic foot and frequently leads to amputation.

The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited, early epub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct-1594_liang_et_al

"CLI describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI is associated with high rates of mortality and morbidity, putting the patients at high-risk for major amputation," said study co-author Dr. Zhong Chao Han of the Beijing Institute of Stem Cells, Health and Biotech. "Mesenchymal stem cells are ideal candidates for transplantation because they have both angiogenic (potential to form new blood vessels) and immunomodulatory properties and are capable of differentiating into three different lineages. The utility of placenta-derived MSCs is poorly understood, so we sought to investigate the efficacy of combined regular therapy and cell therapy in treating diabetes-related CLI."

According to the researchers, human placenta was obtained from full-term cesarean section deliveries with written informed consent of the mother. The use of human-derived cells was approved by the Institutional Biomedical Research Ethics Committee of the Chinese Academy of Medical Science and Peking Union Medical College.

After injection into rats surgically modeled with CLI, the stem cells were traced and counted at various points in time. The researchers found that the stem cell counts decreased dramatically over time, but a few cells differentiated into vascular cells. The infused cells also secreted cytokines, which are small proteins secreted by cells that have a specific effect on the interactions and communications between cells.

"We believe that cytokines secreted by MSCs attract endothelial cells, a type of cells that make up the tissues lining the interior surface of blood vessels," said the researchers. "These cells participate in building new vascular tissues and also inhibit inflammation."

The researchers concluded that their experimental data implied that MSCs improved ischemia recovery in diabetic rats via direct cell differentiation and paracrine (protein-mediated) mechanisms, although the two mechanisms exist simultaneously. The paracrine mechanisms, said the researchers, were likely more important than direct cell differentiation.

"So far, MSC therapy represents a simple, safe and effective therapeutic approach for diabetes and its complications," the researchers concluded. "Our studies lay the groundwork for the transition from the experimental bench to the clinical bedside."

"Diabetes is becoming more prevalent across the globe and stem cell therapy may be a vital approach to serious vascular complications," said Dr. Maria Carolina Oliveira Rodrigues of the Ribeirão Preto Medical School - University of São Paulo, Brazil and section editor of Cell Transplantation. "Future studies should aim to expound upon previous findings in MSC transplantation studies and confirm the efficacy of placenta-derived MSCs for CLI."
-end-
Contact: Zhong Chao Han, 288 Nan Jing Road, Heping District, Tianjin, PR China 300080
Email: hanzhongchao@hotmail.com
Tel: 13802030084
Fax: 86-02266210734

Citation: Liang L, Li Z, Ma T, Han Z, Du W, Geng J, Jia H, Zhao M, Wang J, Zhang B, Feng J, Zhao L, Rupin A, Wang Y, Han ZC. Transplantation of human placenta derived mesenchymal stem cell alleviates critical limb ischemia in diabetic nude rat. Cell Transplant. Appeared or available on-line: August 5, 2016.

The Co-Editors-in-Chief for CELL TRANSPLANTATION are at the Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA and the Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan. Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com

Cell Transplantation Center of Excellence for Aging and Brain Repair

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.